Bioinformatics-Based Identification of HDAC Inhibitors as Potential Drugs to Target EGFR Wild-Type Non-Small-Cell Lung Cancer

Bioinformatics-Based Identification of HDAC Inhibitors as Potential Drugs to Target EGFR Wild-Type Non-Small-Cell Lung Cancer

Patients with EGFR-mutant non-small-cell lung cancer (NSCLC) greatly benefit from EGFR-tyrosine kinase inhibitors (EGFR-TKIs) while the prognosis of patients who lack EGFR-sensitive mutations (EGFR wild type, EGFR-WT) remains poor due to a lack of effective therapeutic strategies. There is an urgent...

Full description

Bibliographic Details
Main Authors: Yizhe Wang, Chunlei Zheng, Wenqing Lu, Duo Wang, Yang Cheng, Yang Chen, Kezuo Hou, Jianfei Qi, Yunpeng Liu, Xiaofang Che, Xuejun Hu
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Oncology
Subjects:
non-small cell lung cancer
histone deacetylase inhibitor
WGCNA
EGFR wild type
metastasis
proliferation
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.620154/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.620154/full

Similar Items